acenocoumarol and Venous-Insufficiency

Topics: Acenocoumarol; Acute Kidney Injury; Aged; Anticoagulants; Aorta, Abdominal; Arterial Occlusive Diseases; Bed Rest; Combined Modality Therapy; Female; Femoral Artery; Heparin, Low-Molecular-Weight; Humans; Iliac Vein; Lumbar Vertebrae; Pulmonary Embolism; Remission Induction; Renal Artery; Renal Dialysis; Spinal Fractures; Thrombectomy; Thrombosis; Venous Insufficiency

Fibrinolysis of 19 patients who developed CVI after deep vein thrombosis was examined. Mean age of patients at the first thrombosis was 31.8 years. For testing fibrinolysis fibrinogen, plasminogen, AP, ECLT, with venous occlusion were determined. In 10 patients t-PA and PAI-1 activities were also measured and plethysmography was carried out. For screening blood coagulation abnormalities of TCT count, PT, APTT, TT, AT III, protein C were tested. The common abnormality was the decreased fibrinolysis. Patients had been on coumarin for 6.14 years before entering the study. Under coumarin treatment 6 patients had relapsed DVT, 4 had crural ulcer and CVI deteriorated in 8 patients. Therefore we added fibrinolysis increasing PPS to coumarin. PPS dose was individually determined by PPS loading test (150-500 mg). Mean observation time with the combined treatment was 2.92 years. Clinical check up and fibrinolysis test were carried out every 6 months. Clinical improvement occurred in 13 patients, (decrease of swelling, pain etc). Two out of 4 patients with stasis ulcer experienced complete healing; in 1 the ulcer territory diminished in size. Maximum venous outflow improved in 7 patients, 3 patients were non-responders. We observed an increase of fibrinolysis in 10 patients. Venous occlusion enhanced the fibrinolysis increasing effect of PPS. The activity reached its maximum by the first control. The fibrinolysis increase and the clinical improvement do not always run parallel, therefore other effects of PPS as the reason for being beneficial in CVI must be considered (antiinflammatory, ect.). Combination of coumarin and PPS seems to be an effective therapy in CVI with decreased fibrinolysis.

Topics: Acenocoumarol; Administration, Oral; Adult; Chronic Disease; Drug Therapy, Combination; Female; Humans; Male; Pentosan Sulfuric Polyester; Thrombophlebitis; Venous Insufficiency